Hematology /Oncology Section Bibliography

Hematology/Oncology Section Bibliography

Book

Alberts DS and Lluria-Prevatt M. Foreward to Bioactive Compounds and Cancer. Editors: Romanglo D and Milner J. Springer Verlag, Berlin, 2010.

Editorial

Garland L, Flores R, Tsao A. Individualizing mesothelioma treatment: Small steps, into a brighter future. Clin Lung Cancer 2010; Nov 1;11(6):371-3.

Chapters

Chapters in scholarly books and monographs

Baker AF and Dragovich T. The Development of Pharmacodynamic Endpoint Models for Evaluation of Therapeutics in Pancreatic Cancer, in: “Drug Discovery in Pancreatic Cancer: Models and Techniques”, eds. H. Han and P. Grippo, Springer-Verlag, 2010.

Jeter JM; Preventive Oncology. EMedicine; http://emedicine.medscape.com/article/1349338-overview ; 2010

Persky DO. Dx/Rx: Lymphoma. 2nd Edition, Sudbury: Jones and Bartlett Publishers. 
 

Journal Articles

Refereed/peer-reviewed journal articles, published on in accepted final form, conference papers

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. For The Breast Cancer Intergroup of North America. Lancet Oncol. [Epub ahead of print]

Algotar AM, Stratton MS, Stratton SP, Hsu CH, Ahmann FR. No effect of selenium supplementation on serum glucose levels in men with prostate cancer. Am J Med. 2010 Aug;123(8):765-8. PubMed PMID: 20670733; PubMed Central PMCID: PMC2913148.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate. 2010 Jun ;70(8):883-8. PubMed PMID: 20135645.

Algotar A.M., Stratton M.S., Xu M.J., Dalkin B.L., Nagle R.B., Hsu C.H., Ahmann F.R., Clark L.C., Stratton S.P. Effect of selenium supplementation on selenium levels within the prostate. Nutrition and Cancer. 2011 Jan;63(1):1-5.

Algotar A.M., Stratton S. P., Ranger-Moore J., Stratton M.S, Hsu C.H., Ahmann F.R., Thompson P.A. Obesity and smoking as risk factors for prostate cancer progression (Accepted at American Journal of Men’s Health, 2010)

Badger T, Segrin C, Figueredo Aurelio, Harrington J, Sheppard K, Passalacqua S, Pasvogel A, Bishop M. “Psychosocial Interventions to Improve Quality of Life in Prostate Cancer Survivors and their Intimate or Family Partners. 2010.

Bookman MA. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann Oncol. 2010 Oct;21 Suppl 7:vii211-vii217. PubMed PMID: 20943617.

Bookman MA. Trials with impact on clinical management: first line. Int J ynecol Cancer. 2009 Dec;19 Suppl 2:S55-62. Review. PubMed PMID: 19955916.

Brown-Glaberman U, Graham A, Stopeck A. A case of metaplastic carcinoma of the breast responsive to chemotherapy with Ifosfamide and Etoposide: improved antitumor response by targeting sarcomatous features. Breast J. 2010 Nov-Dec;16(6):663-5. No abstract available. PMID: 21070449 [PubMed-in process]

Chalasani P, Downey L, Stopeck AT. Caring for the breast cancer survivor: a guide for primary care physicians. Am J Med. 2010 Jun;123(6):489-95. Review. PubMed PMID: 20569749.

Chalasani P, Morgan SS, Butcher D, Jeter JM, HERSH E, Cranmer LD. Retrospective analysis of nanoparticle albumin-encapsulated paclitaxel versus dacarbazine in advanced melanoma. ASCO Proceedings, June 4-8, 2010. Paper #54043.

Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res. 2010 Nov 1;16(21):5320-8. PubMed PMID: 21041183; PubMed Central PMCID: PMC3074583.

Chapman P, Cranmer L, Dixon WG, Hyrich KL, Patterson JR, Symmons DP, Toporcer M, Mastrangelo MJ. (2010) The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol. 37(1):11-9.

Charness, N., Boissy, P., Demiris, G., Krupinski, E. A., Lai, A. M., & Lopez, A. M. Roundtable (2010). Discussion: How human factors can influence the elderly in the use of telemedicine. Telemedicine and e-Health, 16, 860-866. DOI: 10.1089/tmj. 2010.9948.
Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep;3(9):1168-75.Epub 2010 Aug 17. PubMed PMID: 20716633; PubMed Central PMCID: PMC2933312.

Clouser MC, Roe DJ, Foote JA, Harris RB, Alberts DS. Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. Nutr Cancer. 2010;62(8):1058-66. PubMed PMID: 21058193.

Combs D, Baker A, Jordan S, Morgan SS, Pestana L, Herring A, Jeter JM, HERSH E, Cranmer LD. Screening tools for interferon-related cognitive decline in melanoma patients. ASCO Proceedings, June 4-8, 2010. Paper #44615.

Cranmer LD. (2010) Melanoma's radioresistant reputation challenged. Oncology (Williston Park). 24(7):656.

Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist. 2010;15(12):1320-8. Epub 2010 Dec 8. PubMed PMID: 21147868.

Cranmer LD. Melanoma's radioresistant reputation challenged. Oncology (Williston Park). 2010 Jun;24(7):656. PubMed PMID: 20669804.

Darcy KM, Mannel RS, Nilsa MD, Ramirez MD, Alberts DS, Jelonek J, Puehn K, Birrer M. Gynecologic Oncology Group Ovarian Treatment Trials with Specimen Banking and Translational Research. Submitted, Clinical Ovarian Cancer, 3(2):98-112, 2010.

Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, Guzman R, Villalobos I, Di Leo A, Press MF. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplifi cation does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res. 2010 Feb 15;16(4):1281-8. Epub 2010 Feb 9. PubMed PMID: 20145176.
Downey L. The challenge of selecting adjuvant breast cancer chemotherapy for older patients. Oncology (Williston Park). 2010 Jun;24(7):621, 624. PubMed PMID: 20669798.

Green M, Woolery JE, Mahadevan D. Update on Aurora kinase targeted therapeutics in oncology. Expert Opinion on Drug Discovery, Feb. 2011.

Gualberto A, Dolled-Filhart M, Gustabson M, Christiansen J, Wang Y-F, Hixon M Reynolds J, McDonald S, Ang A, Rimm D, Langer C, Blakely J, Garland L, Paz-Ares L, Karp D, Lee A. Molecular Analysis of Non-Small Cell Lung Cancer (NSCLC) Identifies Tumor Subsets with Differential Sensitivity to IGF-IR Inhibition by Figitumumab. Clin Can Res 2010; 10.1158/1078-0432.CCR-10-0089.

Gyurkocza, B., Storb, R.F., Storer, B.E., Chauncey, T.R., Lange, T., Shizuru, J.A., Langston, A.A., Pulsipher, M.A., Bredeson, C.N., Maziarz, R.T., Bruno, B., Petersen, F.B., Maris, M.B., Agura, E., Yeager, A., Bethge, W., Sahebi, F., Appelbaum, F.R., Maloney, D.G., and Sandmaier, B.M. Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia. J. Clin. Oncol. 28: 2859-2867, 2010.

HERSH EM, O’Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R. A phase II clinical trial of nab-paclitaxel in previously-treated and chemotherapy-naïve patients with metastatic malignant melanoma. Cancer. 116(1): 155-163, 2010.
HERSH EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Epub ahead of print, Invest New Drugs. January 16, 2010.

Hess LM, Chambers SK, Hatch K, Hallum A, Janicek MF, Buscema J, Borst M, Johnson C, Slayton L, Chongpison Y, Alberts DS. Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. J Support Oncol. 2010 Nov-Dec;8(6):252-8. PubMed PMID: 21265392.

Hostetter G, Kim S, Savage S, Gooden G, Alla L, Barrett M, Zhang J, Watanabe A, Einspahr J, Alberts D, Prasad A, Nickoloff B, Carpten J, Trent J, Bittner M. Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples. Nucleic Acids Res. 2010 Feb;38(2):e9. PMCID: PMC2811007.

Jha AK, Kupinski MA, Rodríguez JJ, Stephen RM, Stopeck AT. Evaluating segmentation algorithms for diffusion-weighted MR images: a task-based approach. Proc Soc Photo Opt Instrum Eng. 2010 Feb 27; 7627. pii: 76270L (2010).PMID: 21152379

Jha AK, Rodríguez JJ, Stephen RM, Stopeck AT. A Clustering Algorithm for Liver Lesion Segmentation of Diffusion-Weighted MR Images. Proc IEEE Southwest Symp Image Anal Interpret. 2010 May 23; 2010:93-96.PMID: 21151837

Kantarjian, H.M., Erba, H.P., Claxton, D., Arellano, M., Lyons, R.M., Kovascovics, T., Gabrilove, J., Craig, M., Douer, D., T., Maris, M., Petersdorf, S., Shami, P.J., Yeager, A.M., Eckert, S., Abichandani, R., and Faderl, S. Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors. J. Clin. Oncol. 28: 549-555, 2010.

Kim YH, Coon C, Baker AF, and Powis G . Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase. 2010 (Nov) Cancer Chemotherapy and Pharmacology.

Koyanagi K, O’Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, HERSH E, Richards J, Weber JS, Hoon DS. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (In Press), 2010.

Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; on behalf of the Gynecologic Cancer InterGroup. Prognostic Relevance of Uncommon Ovarian Histology in Women with Stage III/IV Epithelial Ovarian Cancer. Int J Gynecol Cancer 2010;20:945-952. PMID: 20683400.

Mahadevan D. and Fisher RI. Novel Therapeutics for Aggressive non-Hodgkin Lymphoma. J. Clinical Oncology, March. 2011.

Mahadevan D, Plummer R, Squires M, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H. A Phase I Pharmacokinetic and Pharmacodynamic Study of AT519, a Cyclin-dependent Kinase Inhibitor in Patients with Refractory Solid Tumors. Submitted to Clinical Cancer Research, February 2010 /Ann Oncol. 2011 Feb 16. PMID: 21325451.

Marman M, Moon J, Wilczynski S, López AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS. Single Agent Carboplatin Versus Carboplatin plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer: Final Survival Results of a SWOG (SO200) Phase 3 Randomized Trial. Gynecology Oncology. 2010 Mar:116(3):323-325. Epub 2009 Dec 30.

Miller JA, Hakim IA, Chew W, Thompson P, Thomson CA, Chow HH. Adipose tissue accumulation of d-limonene with the consumption of a lemonade preparation rich in d-limonene content. Nutr Cancer. 2010;62(6):783-8. PubMed PMID: 20661827.

Miller, J.A., Hakim, I.A., Thomson, C., Thompson, P., Chow, H-H.S. “Preferential distribution and accumulation of d-limonene in adipose tissue in humans following the consumption of a lemonade preparation rich in d-limonene content,” Nutrition and Cancer, 62, 783-788, 2010.

Nguyen, N, Bishop, MC, Borok, T, Welsh, J, Hamilton, R, Cohen, D, Nguyen, L, Vincent, V. “Pattern of Failure Following Chemoradiation for Locally Advanced Non-small Cell Lung Cancer: Potential Role for Stereotactic Body Radiotherapy”. Anticancer Research, 30:953-962, 2010.

Olson ER, Melton T, Dickinson SE, Dong Z, Alberts DS, Bowden GT. Quercetin potentiates UVB-Induced c-Fos expression: implications for its use as a chemopreventive agent. Cancer Prev Res (Phila). 2010 Jul;3(7):876-84. Epub 2010 Jun 15. PubMed PMID: 20551291; PubMed Central PMCID: PMC2925138.

Persky DO, Moskowitz, CH, Filatov A, Saxena R, Haiyan C, Teruya-Feldstein. J. High dose Chemoradiotherapy and ASCT May Overcome the Prognostic Importance of Biologic Markers in Relapsed/Refractory Hodgkin’s Lymphoma. Appl Immunohistochem Mol Morphol 2010 Jan;18 (1):35-40. PMID 19701081

Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Persky DO, Miller TP, Mahadevan D. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol. 2011 Feb 1. [Epub ahead of print] PMID: 21291867.

Ramanathan RK, Abbruzzese J, Dragovich T, Kirkpatrick L, Guillen JM, Baker AF, Pestano LA, Green S, Von Hoff DD. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol. Published online May 12, 2010.

Rimsza L, Wright G, Schwartz M, Chan W, Jaffe E, Gascoyne R, Campo E, Rosenwald, A, Ott G. Cook J, Tubbs R, Braziel R, Delabie J, Miller T, Staudt L. Accurate Classification of Diffuse Large B cell Lymphoma into Germinal Center and Activated B cell Subtypes Using a Nuclease Protection Assay on Formalin Fixed Paraffin Embedded Tissues Clin Can Res 10-2573 Dec 2010.

Roman NO, Samulitis B, Wisner L, Landowski TH, Dorr RT. Imexon enhances gemcitabine
cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemother. Pharm, 2011 Jan;67(1):183-92. Epub 2010 Mar 26.

Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;117:324-9. PMID: 20185168.

Schaffel R, Hedvat CV, Teruya-Feldstein J, Persky D, Maragulia J, Lin D, Portlock CS, Moskowitz CH, Zelenetz AD. Prognostic Impact of Proliferative Index Determined by Quantitative Image Analysis and the Mantle Cell Lymphoma International Prognostic Index in Patients with Mantle Cell Lymphoma. Ann Oncol, 2010 Jan; 21(1):133-9

Sekulic A, Kim SY, Hostetter G, Savage S, Einspahr JG, Prasad A, Sagerman P, Curiel-Lewandrowski C, Krouse R, Bowden GT, Warneke J, Alberts DS, Pittelkow MR, DiCaudo D, Nickoloff BJ, Trent JM, Bittner M. Loss of inositol polyphosphate 5-phosphatase is an early event in development of cutaneous squamous cell carcinoma. Cancer Prev Res (Phila). 2010 Oct;3(10):1277-83. Epub 2010 Sep 28. PubMed PMID: 20876729; PubMed Central PMCID: PMC2955780.

Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA. Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res. 2010 May 15;16(10):2803-10. Epub 2010 May 11.PMID: 20460489

Stasik C, Nitta H, Zhang W, Mosher C, Cook J, Tubbs R, Unger J, Brooks T, Persky DO, Wilkinson S, Grogan T, Rimsza L. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica, 2010 Apr;95(4) 597-603 PMID: 20378577

Squires M, Cooke L, Lock V, Qi W, Lewis E, Yule M, Thompson N, Lyons J, Mahadevan D. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8.

Stratton SP, Alberts DS, Einspahr JG, Sagerman PM, Warneke JA, Curiel-Lewandrowski C, Myrdal PB, Karlage KL, Nickoloff BJ, Brooks C, Saboda K, Yozwiak ML, Krutzsch MF, Hu C, Lluria-Prevatt M, Dong Z, Bowden GT, Bartels PH. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila). 2010 Feb;3(2):160-9. Epub 2010 Jan 26. PubMed PMID: 20103724.

Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (Phila). 2010 Aug;3(8):1035-43. Epub 2010 Jul 20. PubMed PMID: 20647337.

Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3;362(22):2053-65.PMID: 20519679

Thomson CA, Stopeck AT, Bea JW, Cussler E, Nardi E, Frey G, Thompson PA. Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets. Nutr Cancer. 2010 Nov;62(8):1142-52.PMID: 21058203

Thompson PA, Hsu CH, Green S, Stopeck AT, Johnson K, Alberts DS, Chow HH. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. Cancer Prev Res (Phila). 2010 Jan;3(1):101-7. PubMed PMID: 20051377.

Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC; Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. for the Gynecologic Cancer Intergroup/National Cancer Institute Writing Committees. Current academic clinical trials in ovrian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting. Intl J Gynecologic Cancer, 20(7):1290-1298, 2010.

Wall, D.A., Chan, K.W., Nieder, M.L., Hayashi, R.J., Yeager, A.M., Kadota, R., Przepiorka, D., Mezzi, K., Kletzel, M. Safety, Efficacy, and Pharmacokinetics of Intravenous Busulfan in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Pediatr. Blood Cancer 54: 291-298, 2010.

Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O’Day S, Sato T, Dorr R, Grenier K, and HERSH EM. A Phase 1-2 Study of Imexon Plus Dacarbazine in Patients With Unresectable Metastatic Melanoma. Cancer, 116:3683-91, 2010.

Wenqing Qi, Xiaobing Liu, Laurence S. Cooke, Daniel O. Persky, Thomas P. Miller, Matthew Squires, Daruka Mahadevan. AT9283, a Novel pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth in aggressive B-cell non-Hodgkin’s lymphoma. Int. J. of Cancer, March 2011.

Weinstein RS, McNeely RA, Holcomb MJ, Sotelo, MJ, López AM, Erps KA, Martin CJ, Krupinski EA, Graham AR, Barker GP. Technologies for Interprofessional Education. The Interprofessional Education Distributed “e-Classroom-of-the-Future”. Journal of Allied Health. J Allied Health 2010; 39 (3 pt 2): 238-245.

Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Kent Osborne C, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Mar 23.

Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB. Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer. Clin Cancer Res. 2010 Dec 15;16(24):6169-6176.PMID: 21169260

Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group Study. Cancer. 2010 Sep 22. [Epub ahead of print] PubMed PMID: 20862744.

Zou, C., Liu, H., Feugang, J., Hao, S., Chow, H-H.S., Garcia, F. “Green tea compound in chemoprevention of cervical cancer,” International Journal of Gynecological Cancer 20:617-624, 2010.

Meeting Abstracts

Conference paper abstracts and poster abstracts

Abhinav K. Jha, Matthew A. Kupinski, Jeffrey J. Rodriguez, Renu M. Stephen and Alison T. Stopeck, "ADC Estimation of Lesions in Diffusion-Weighted MR Images: A Maximum-Likelihood Approach", 2010 IEEE Southwest Symp. on Image Analysis and Interpretation

Abhinav K. Jha, Jeffrey J. Rodriguez, Renu M. Stephen and Alison T. Stopeck, "A Clustering Algorithm for Liver Lesion Segmentation of Diffusion-Weighted MR Images", 2010 IEEE Southwest Symp. on Image Analysis and Interpretation.

Alberts DS. Should endpoints for trials in recurrent disease vary from those of first-line trials? 4th Ovarian Cancer Consensus Conference, UBC Life Sciences institute, Vancouver, BC, 2010.

Algotar AM, Thompson PA, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, and Stratton SP. Effect of Aspirin, other NSAIDs and statins on PSA and PSA velocity. The Prostate. Published Online: 4 Feb 2010 Abstract.

Anwer, F., Green, M.R., and Yeager, A.M. Effective Primary Mobilization of Autologous Peripheral Blood Stem Cells with Granulocyte Colony-Stimulating Factor and Plerixafor in Lenalidomide-Treated Patients with Multiple Myeloma. Blood 116: 927, 2010 (abstract no. 2254). (Poster presentation, 2010 Annual Meeting, American Society of Hematology)

Anwer, F., Green, M., and Yeager, A.M. Initial Mobilization of Autologous Peripheral Blood Stem Cells with Granulocyte Colony-Stimulating Factor and Plerixafor in Patients with Multiple Myeloma: A Prospective Comparison in Lenalidomide- and Non-Lenalidomide-Treated Patients. Biol. Blood Marrow Transplant. 17 (Suppl. 2): in press, 2011. (Accepted for poster presentation, 2011 Annual Meeting, American Society for Blood and Marrow Transplantation)

Baker AF, Pineda CT, Maine E, Dragovich T. Effect of R1507, an anti-IGF-1R monocolonal antibody, on sensitization of pancreatic cancer cell lines to mTOR inhibition. 2010 GI ASCO, Orlando, FL.

Burger RA, Brady MF, Bookman MA, Walker JL, Homesley HD, Fowler J, Monk BJ, Greer BE, Boente M, Liang SX. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1)

Campen, C.J., Armstrong, E.P., Christian, J.A., Hadeed, S., and Yeager, A.M. Comparative Cost-Effectiveness of Plerixafor Plus Granulocyte-Colony Stimulating Factor Versus Cyclophosphamide Plus Granulocyte-Colony Stimulating for Autologous Peripheral Blood Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma. Biol. Blood Marrow Transplant. 16 (Suppl. 2): S206, 2010 (abstract no. 129). (Poster presentation, 2010 Annual Meeting, American Society for Blood and Marrow Transplantation)

Campen, C.J., Yeager, A.M., Green, M.R., and Armstrong, E.P. Comparative Cost-Effectiveness of Plerixafor Plus Granulocyte Colony-Stimulating Factor Versus Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor for Autologous Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma. Biol. Blood Marrow Transplant. 17 (Suppl. 2): in press, 2011. (Accepted for poster presentation, 2011 Annual Meeting, American Society for Blood and Marrow Transplantation)

Chalasani P, Morgan SS, Butcher D, Jeter JM, Hersh E, Cranmer LD. Retrospective analysis of nanoparticle albumin-encapsulated paclitaxel versus dacarbazine in advanced melanoma. ASCO Proceedings, June 4-8, 2010. Paper #54043.

Clemens Wendtner, Peter Hillmen, Daruka Mahadevan, Stephan Stilgenbauer, Lutz Uharek, Steven Coutré, Olga Frankfurt, Adrian Bloor, Francesc Bosch, Richard R. Furman, Eva Kimby, John G. Gribben, Marco Gobbi, Luke Dreisbach, David D. Hurd, Mikkael A. Sekeres, Alessandra Ferrajoli, Sheetal Shah, Jennie Zhang, Laure Moutouh de Parseval, Asher Chanan-Khan. Final Results of the Phase 1 Study of Lenalidomide in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). ASH #1376) Poster.

Combs D, Baker A, Jordan S, Morgan SS, Pestana L, Herring A, Jeter JM, Hersh E, Cranmer LD. Screening tools for interferon-related cognitive decline in melanoma patients. ASCO Proceedings, June 4-8, 2010. Paper #44615.

Heather Cornnell, Arig Ibrahim Hashim, Gary Martinez, Amanda F. Baker and Robert Gillies Manipulating the Tumor Vasculature. World Molecular Imaging Congress Sept. 8-11, 2010 in Kyoto, Japan.

Curiel-Lewandrowski, C., Swetter, S., Einspahr, J., Hu, C-C., Saboda, K., Nagle, R., Sagerman, P., Tangrea,J., Parnes, H., Chow, H-H.S. “Phase IIa placebo controlled trial of sulindac in individuals at increased risk for melanoma: preliminary findings.” Ninth Annual American Association for Cancer Research International Conference, Philadelphia, PA, November 7-10, 2010.

Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Stratton SP, Liotta L, Pellicani G, Krouse R, Prasad A, Deng J, Bowden GT, Petricoin EF. Functional protein pathway activation mapping for the progression of normal skin to squamous cell carcinoma. Amer Assn for Can Res, 2010.

Flowers CR, Taylor M, Byrtek M, Hirata JH, Cerhan J, Hainsworth J, Link B, Miller TP, Dillon H, Friedberg JW. Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS) Blood (ASH Annual Meeting Abstracts), Nov 2010;116:1768

Friedberg JW, Unger JM, Burack RB, W. Gopal AK, LeBlanc ML, Ajay K Gopal, Press, OW, Miller TP, Fisher RI. R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:590

Fuchs CS, Tepper JE, Niedzqiecki D, Hollis D, Mamon HJ, Swanson RS, Haller DG, Dragovich T, Alberts SR, Bjarnason G, Willett CG, Goldberg RM, Venook AP, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal (GE) adenocarcinoma using epiubicin, cisplatin and infusional (C1) 5-FU (ECF) before and after C1 5-FU and radiotherapy (RT): Results from Intergroup trial CALGB 80101. Proc Am Soc Clin Oncology, 2011.

Garland L. Accrual to US phase III clinical trials in NSCLC: Women and race/ethnic group under-representation. Proc ASCO, 2010.

Joseph R Garlich, PhD, Michael D Becker, Candace F Shelton, Wenqing Qi, PhD, Xiaobing Liu, Laurence Cooke and Daruka Mahadevan, MD, PhD. Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies. (ASH #1783) Poster.

Gerfen, A.D., Campen, C.J., Yeager, A.M., and Green, M.R. Chemomobilization with Cyclophosphamide and Filgrastim in Multiple Myeloma Patients Following Lenalidomide Treatment. Biol. Blood Marrow Transplant. 17 (Suppl. 2): in press, 2011. (Accepted for poster presentation, 2011 Annual Meeting, American Society for Blood and Marrow Transplantation)

Glazer ES, Bartels PH, Yozwiak M, Prasad AR, Bartels HG, Alberts DS, Krouse RS. Karyometry of Cutaneous squamous cell carcinoma discriminates between aggressive and nonaggressive phenotypes. Soc Surgical Onc, 2010.

Gottlieb RH, Cranmer LD. Quantitative Visual Based Scoring: Improving Early CT Prediction of Outcome of Treated Metastatic Melanoma Patients Compared with the Current Response Evaluation Criteria in Solid Tumors Standard. Annual Meeting of the Society for Imagine Informatics in Medicine (SIIM). Washington, DC. June 2-5, 2011.

Hersh E, Millward M, Elias I, Iglesias J. An open-label, multicenter, phase III trial of nab-paclitaxel (NP) vs dacarbazine (DTIC) in previously untreated patients (PTs) with metastatic malignant melanoma (MMM). ASCO Proceedings, June 4-8, 2010. Paper #44215.

Gyurkocza, B., Storb, R.F., Storer, B., Chauncey, T., Lange, T., Laport, G.G., Langston, A., Pulsipher, M., Bredeson, C.N., Maziarz, R., Bruno, B., Petersen, F., Maris, M., Agura, E., Yeager, A.M., Bethge, W., Sahebi, F., Appelbaum, F., Maloney, D.G., Estey, E., and Sandmaier, B.M. A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse after Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-transplant Variables. Blood 116: 1415, 2010 (abstract no. 3450). (Poster presentation, 2010 Annual Meeting, American Society of Hematology)

M Iannone, L Pennick, M Damiano, K Weihs, A Ratts, A Stopeck. “Prevalence of Depression in Adults with Hemophilia”, XXIX International Congress of the World Feeration of Hemophilia, July 2010 Buenos Aires, Argentina.

Kahl B, Roberts AW, Seymour JF, Advani RH, Persky DO, Yang J, Cui Y, Busman T, Krivoshik A, Enschede S, Humerickhouse R. Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies Blood (ASH Annual Meeting Abstracts), Nov 2010;116: 3943

Koyanagi K, O’Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, HERSH E, Richards J, Weber JS, Hoon DS. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (In Press), 2010.

Lipton, A. Stopeck, R. von Moos, D. H. Henry, G. E. Richardson; A Meta- analysis of Results From Two Randomized, Double-blind Studies of Denosumab Versus Zoledronic Acid (ZA) For Treatment of Bone Metastases; Oral Abstract Session; 2010 ASCO Annual Meeting; June 5, 2010

Mahadevan D, Cooke L, Lui X, Persky DO, Spier C, Miller TP, Wenqing Q. Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin’s Lymphoma. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:3933

Daruka Mahadevan, Mark C. Lanasa, Maria Whelden, Susan J. Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, and Leonard T. Heffner. First-in-Human Phase I Dose Escalation Study of a Humanized Anti-CD200 Antibody (Samalizumab) in Patients with Advanced Stage B cell Chronic Lymphocytic Leukemia (CLL) or Multiple Myeloma (MM). (ASH #2465) Poster.

Mahadevan D, Liu, X, Persky DO, Miller TP, Squires MS, Wenqing Q. AT9283, a Novel Pan- Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin’s Lymphoma. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:3930

Marshall JR, Tangen CM, Sakr W, Wood DP, Lippman SM, Jarrard DF, Alberts DS, Berry DL, Crawford ED, Thompson I. Southwest Oncology Group (SWOG) trial S9917: Randomized phase 3 trial of selenium supplementation to prevent prostate cancer among men with high grade prostatic intraepithelial neoplasias (HGPIN). Amer Soc Clin Oncol, 2010

Mehl, M.R. Robbins, M. L., & López, A. M. The daily interactions of couples coping with breast cancer: How is naturalistically observed disclosure related to psychological adjustment? Symposium contribution to be delivered at the annual meeting of the Society for Personality and Social Psychology. Las Vegas, NV. January 2010.

Morgan SS, Cranmer LD. Combination of molecularly-targeted and cytotoxic chemotherapies for the treatment of synovial sarcoma cell lines. 16th Annual Conference of the Connective Tissue Oncology Society. Paris, France, November 2010.

Morgan SS, Wang ZJ, Taverna P, Cranmer LD. Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, November 2010. (Abstract #193).

Azra Raza, MD, Naomi Galili, PhD, Scott E. Smith, MD, PhD, FACP, John Godwin, MD, Ralph V. Boccia, MD, Han Myint, MD , Daruka Mahadevan, MD, PhD, Deborah Mulford, MD, Mark Rarick, MD, Mary Ann Allison, MD, Ostap G. Melnyk, MD, Lisa Meng, Marsha Jones, MD, Gail L Brown, MD, Shelby Young, RN, and Mikkael A. Sekeres, MD. Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). (ASH #2910) Poster.

Roberts W, Advani R, Kahl B, Persky D, Xiong H, Cui Y, Busman T, Krivoshik A, Enschede S, Humerickhouse R. Phase 1 Study of Navitoclax (ABT-23) Plus Rituximab in CD20-Positive Lymphoid Malignancies. 15th Congress of the European Hematology Association. 2010 Abstract 0894

Sorror, M.L., Storer, B., Sandmaier, B.M., Franke, G.N., Laport, G., Chauncey, T., Agura, E., Maris, M., Wade, J., Pulsipher, M., Maziarz, R., Sahebi, F., McSweeney, P., Bruno, B., Andersen, N., Yeager, A.M., Niederwieser, D., Blume, K., Storb, R., and Maloney, D.G. Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) after Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors. Blood 116: 553, 2010 (abstract no. 1292). (Poster presentation, 2010 Annual Meeting, American Society of Hematology)

Stopeck A., de Boer R., Fujiwara Y, Tonkin K., Yardley D. Denosumab vs Zoledronic Acid for the Treatment of Bone Metastases: Skeletal-Related Events in a Meta-analysis from Two Randomised, Double-blind Studies; Presented at MASCC2010 International Symposium in Vancouver, BC; June 26, 2010

Stopeck AT, Unger JM, Rimsza LM, Farnsworth B, LeBlanc ML, Iannone M, Fisher RI, Miller TP. Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:591

Tardif HL, Song Y, Goldman BH, Spier CM, LeBlanc ML, Rimsza LM, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Athracycline-Based Tehrapy for Aggressive B-Cell Non-Hodgkin Lymphomas. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:321

Tew WP, Java J, Chi D, Menzin A, Lovecchio JL, Bookman MA, Lichtman SM. Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182). J Clin Oncol 28:15s, 2010 (suppl; abstr 5030)

T. Trouard, P. Thompson, C. Huang, M. Altbach, M. Kupinski, D. Roe, K. Fitzpatrick, P. Granstrom, G. Frey, S. Squire, V. Poulin, and A. Stopeck. Fat water ratio and diffusion-weighted MRI applied to the measure of breast density as a cancer risk biomarker. Proceeding of the International Society for Magnetic Resonance in Medicine, 2010, Stockholm, Sweden, Pg. 4749.

Wenqing Qi, Xiaobing Liu, Catherine Spier, Daruka Mahadevan. Effective Targeting of Peripheral T-cell Lymphoma (NOS) with MP470, a novel Multi-targeted Tyrosine Kinase Inhibitor. (T-Cell Lymphoma Forum) Poster.

W. Qi, L. Cooke, X. Liu, D. Persky, T. Miller, M. Squires*, D. Mahadevan. AT9283, a Novel pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth in aggressive B-cell non-Hodgkin’s lymphoma. (ASH #3930) Poster.

W. Qi, L. Cooke, X. Liu, D. Persky, C. Spier, T.P. Miller, D. Mahadevan. Addition of Rituximab to MLN8237 an Aurora A kinase inhibitor plus Vincristine or Docetaxel has Synergistic Anti-tumor Activity in a Mouse Model of Aggressive B-cell non-Hodgkin’s Lymphoma. (ASH #3933) Poster.

Xiaobing Liu, Wenqing Qi, Laurence Cooke, E. M. Kithsiri Wijeratne, Ya-mingXu, Marilyn T. Marron, A. A. Leslie Gunatilaka, and Daruka Mahadevan. An Analogue of Withaferin A Up-regulates the MAPK and Glutathione ‘Stress’ Pathways Prior to Activation of Apoptosis in Pancreatic cancer cells (AACR #1643 ) Poster.

Other Publications

Book reviews, commentaries, editorials or other non-refereed scholarly material, etc.

Alberts DS. “High time” for a phase III, dosing schedule trial in U.S. women. Oncology News, 2010.

Alberts DS, Hess LM, Clouser MC (eds). Intraperitoneal Therapy for Ovarian Cancer, Springer-Verlag, 2010.

Bookman MA. Current Chemotherapy of Ovarian Cancer. In: Intraperitoneal Therapy for Ovarian Cancer. Eds: Alberts DS, Clouser MC, Hess LM. Springer-Verlag, Berlin Heidelberg. Pp: 7-25, 2010

Campen C, Baker AF, Dragovich T, Current and Future Management Strategies in Pancreatic Cancer." 2011 (April) American Journal of Health-System Pharmacy.

Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. Am J Health Syst Pharm, 2011.

Mahadevan D, Plummer R, Squires M, Rensvold D, Kurtin S, Pretzinger C, Dragovich T, Adams J, Lock V, Smith DM, Von Hoff D, Calvert H. A Phase I Pharmacokinetic and Pharmacodynamic Study of AT519, a Cyclin-dependent Kinase Inhibitor in Patients with Refractory Solid Tumors. Annals of Oncology, 2011.

Milner JA and Romagnolo D. (Ed). Alberts DS and Lluria-Prevatt, M. In: Bioactive Compounds and Cancer, Humana Press, 2010.

Media/Video and Audio

Cranmer, Lee

Interviewee: Experimental drug shows promise in melanoma treatment. Arizona Cancer Center. http://azcc.arizona.edu/node/2572 Tucson, AZ. 11JUN10

Interviewee: Driving behind the wheel could cause skin cancer. KVOA-TV. http://www.kvoa.com/news/ho-driving-behind-the-wheel-could-cause-skin-ca...
Tucson, AZ. 24MAY10

Presenter: Recent advances in early melanoma diagnosis and treatment: Where we are today and might be tomorrow. Arizona Cancer Center Director’s Circle. Arizona Inn. Tucson, AZ. 10MAY10

Interviewee: Melanoma: characteristics and prevention. The Daily Male Radio Show with Dave Sitton. KQTH-FM 104.1. 02MAY10

Presenter: Community Lecture Series: Melanoma. Oro Valley Public Library. Oro Valley, AZ. 03MAR10

Audio Interviews

López, Ana Maria
 

Radio Nueva Vida, Spanish Language from California- “Breast Cancer Awareness Month”- NCI, October 29, 2010.

“VIDA: Quinta Conferencia Anual del Cáncer del Seno en la Mujer Latina”, TV interview, Telemundo, Tucson, AZ, September 26, 2010.

Telemedicine Use in Cancer Centers. Oncology Net Guide Magazine. Interview. June 22, 2010. Tucson, AZ.

Radio Nueva Vida, Spanish Language from California, Interview for “Cervical Cancer in Latinas”.  (Spanish) March 2, 2010.

Videos

López, Ana Maria
Bryn Mawr Hepburn Tribute video (for Hepburn Medal & Celebration 2011) December 8, 2010. Tucson, AZ.

“Breaking through the Legislative Firewall”, ACP video of ACP physicians addressing Congress. November 2010.

“Woman to Woman: Let’s talk About Breast Cancer”. Video premiere for the Community. Arizona Cancer Center. October 30, 2010. Tucson, AZ.

“Mujer a Mujer: Una Pl’atica Sobre Cáncer de Seno.” Video premiere for the Community. Arizona Cancer Center. August 28, 2010. Tucson, AZ.

Magazines and Newspapers

Cranmer, Lee

Interviewee: Influx of funding impels collaborative explorations to study sarcoma as behavior model for others. Oncology NEWS International. (F. Lowry). 01SEP10

Interviewee: Trial heralding a new day for melanoma meets with guarded enthusiasm. Oncology NEWS International. (W. Alexander, S. Pal). 13JUL10

López, Ana Maria

Salud! – E- publication Newsletter, Arizona Chapter of the American College of Physicians (ACP). Abstracts from the 2010 Annual Scientific Meeting, Vol. I, Issue I, Dec. 2010.

Harmony Magazine: a Humanities Magazine; University of Arizona College of Medicine; Poems: “My Father’s Daughter;” “The Sounds of Violence.”

Telemedicine: Enhancing Rural Cancer Care, Oncology Magazine, Vol.11, No. 7, July 2010 . Quoted- “Dedication in the Desert.”

Web Pages

Bishop, Maria C CEPEC - Comprehensive Education in Palliative/End of Life Care (www.cepec.arizona.edu)

Lopez, Ana Maria Arizona Telemedicine Program (APT) site (http://www.telemedicine.arizona.edu )